World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
128
Citations
81210
World Ranking
2655
National Ranking
1483

Overview

Eric J. Small is affiliated with the University of California, San Francisco in the United States. Their research primarily spans the fields of Medicine and Biochemistry, Genetics and Molecular Biology, with a focus on oncology-related topics.

The scientist's work covers several subfields including Pulmonary and Respiratory Medicine, Oncology, Cancer Research, Radiology, Nuclear Medicine and Imaging, and Surgery. Their research interests concentrate on topics such as Prostate Cancer Treatment and Research, Radiopharmaceutical Chemistry and Applications, Prostate Cancer Diagnosis and Treatment, Cancer, Lipids, and Metabolism, Cancer Genomics and Diagnostics, PARP inhibition in cancer therapy, and Cancer Immunotherapy and Biomarkers.

Eric J. Small has contributed to multiple recent scientific papers, demonstrating involvement in clinical and genetic studies related to prostate cancer. Notable recent publications include:

  • Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019, 2020, European Urology
  • The DNA methylation landscape of advanced prostate cancer, 2020, Nature Genetics
  • Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer, 2023, Journal of Clinical Oncology
  • Apalutamide and Overall Survival in Prostate Cancer, 2020, European Urology
  • Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial, 2023, Annals of Oncology

Frequent co-authors collaborating with Eric J. Small include:

  • Rahul Aggarwal
  • Felix Y. Feng
  • Jonathan Chou
  • David A. Quigley
  • Terence W. Friedlander

Eric J. Small's publications have appeared most often in the following venues:

  • Journal of Clinical Oncology
  • Annals of Oncology
  • Cancer Research
  • European Urology
  • Clinical Cancer Research

Best Publications

  • Sipuleucel-T immunotherapy for castration-resistant prostate cancer.

    Philip W. Kantoff;Celestia S. Higano;Neal D. Shore;E. Roy Berger

  • Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

    Daniel P. Petrylak;Catherine M. Tangen;Maha H.A. Hussain;Primo N. Lara

  • Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy

    Charles J. Ryan;Matthew R. Smith;Johann S. De Bono;Arturo Molina

  • Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.

    Howard I. Scher;Susan Halabi;Ian Tannock;Michael Morris

  • Placebo-Controlled Phase III Trial of Immunologic Therapy with Sipuleucel-T (APC8015) in Patients with Metastatic, Asymptomatic Hormone Refractory Prostate Cancer

    Eric J. Small;Paul F. Schellhammer;Celestia S. Higano;Charles H. Redfern

  • Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3

    Howard I. Scher;Michael J. Morris;Walter M. Stadler;Celestia Higano

  • Metabolic Imaging of Patients with Prostate Cancer Using Hyperpolarized [1-13C]Pyruvate

    Sarah J. Nelson;John Kurhanewicz;Daniel B. Vigneron;Peder E. Z. Larson

  • Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology

    James L. Mohler;Emmanuel S. Antonarakis;Andrew J. Armstrong;Anthony V. D'Amico

  • Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer

    Matthew R Smith;Fred Saad;Simon Chowdhury;Stéphane Oudard

  • Eligibility and Response Guidelines for Phase II Clinical Trials in Androgen-Independent Prostate Cancer: Recommendations From the Prostate-Specific Antigen Working Group

    Glenn J. Bubley;Michael Carducci;William Dahut;Nancy Dawson

  • Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206

    Brian I Rini;Susan Halabi;Jonathan E. Rosenberg;Walter M. Stadler

  • Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study

    Charles J. Ryan;Matthew R. Smith;Karim Fizazi;Fred Saad

  • Phase III Trial of Bevacizumab Plus Interferon Alfa Versus Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: Final Results of CALGB 90206

    Brian I. Rini;Susan Halabi;Jonathan E. Rosenberg;Walter M. Stadler

  • Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with Sipuleucel-T in advanced prostate cancer

    Celestia S. Higano;Paul F. Schellhammer;Eric J. Small;Patrick A. Burch

  • Immunotherapy of Hormone-Refractory Prostate Cancer With Antigen-Loaded Dendritic Cells

    Eric J. Small;Paige Fratesi;David M. Reese;George Strang

  • Prognostic Model for Predicting Survival in Men With Hormone-Refractory Metastatic Prostate Cancer

    Susan Halabi;Eric J. Small;Philip W. Kantoff;Michael W. Kattan

  • Selection for Androgen Receptor Mutations in Prostate Cancers Treated with Androgen Antagonist

    Mary-Ellen Taplin;Glenn J. Bubley;Yoo-Joung Ko;Eric J. Small

  • Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial

    Toni K. Choueiri;Susan Halabi;Ben L. Sanford;Olwen Hahn

  • Prostate Cancer, Version 1.2016

    James L. Mohler;Andrew J. Armstrong;Robert R. Bahnson;Anthony Victor D'Amico

  • Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583).

    Eric J. Small;Susan Halabi;Nancy A. Dawson;Walter M. Stadler

Frequent Co-Authors

Susan Halabi
Susan Halabi Duke University
Matthew R. Smith
Matthew R. Smith Harvard University
Tomasz M. Beer
Tomasz M. Beer Oregon Health & Science University
Lawrence Fong
Lawrence Fong University of California, San Francisco
Celestia S. Higano
Celestia S. Higano University of Washington
Fred Saad
Fred Saad University of Montreal
Philip W. Kantoff
Philip W. Kantoff Memorial Sloan Kettering Cancer Center
Michael J. Morris
Michael J. Morris Memorial Sloan Kettering Cancer Center
Kim N. Chi
Kim N. Chi BC Cancer Agency
Martin E. Gleave
Martin E. Gleave University of British Columbia

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in Medicine doesn’t always mean taking the traditional path of becoming a medical doctor. Online nursing and allied health degrees offer flexible and rewarding alternatives, especially for those looking to balance studies with existing responsibilities.

For current RNs aspiring to top-level practice and leadership, DNP online programs offer advanced clinical training. Some applicants seek easy DNP programs that feature streamlined admissions or accelerated course structures. These options can make doctoral study more accessible, yet still demand a rigorous academic approach.

If you want to quickly start working in the nursing profession, LPN program options online provide fast-track pathways to licensure. These can be especially appealing for career changers or those wishing to enter the healthcare workforce sooner.

Specializing further, those interested in mental health can opt for the shortest online PMHNP programs, targeting a rapidly growing field with high demand.

Each of these online pathways comes with unique timelines and challenges, but can provide the skills and credentials necessary for a rewarding healthcare career in the U.S.

Best Scientists Citing Eric J. Small

Trending Scientists